COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR FIRST-LINE TREATMENT IN PATIENTS WITH PERSISTENT, RECURRENT, AND METASTATIC CERVICAL CANCER IN THE UNITED STATES: RESULTS FROM THE FINAL ANALYSIS OF TRIAL

被引：0
|
作者：
Swami, S. [1 ]
Hale, O. [2 ]
Thornton, I [3 ]
Muston, D. [4 ]
Monberg, M. J. [4 ]
Monk, B. J. [5 ]
机构：
[1] MSD UK Ltd, London, England
[2] Lumanity, London, England
[3] Lumanity, Sheffield, S Yorkshire, England
[4] Merck & Co Inc, Rahway, NJ USA
[5] Creighton Univ, Univ Arizona, HonorHlth Res & Innovat Inst, Phoenix, AZ USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE673
引用
收藏
页码：S183 / S183
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR FIRST-LINE TREATMENT IN PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN THE UNITED STATES
    Monk, Bradley
    Boer, Jennifer
    Van Hees, Frank
    Van Mens, Sophie
    Swami, Shilpi
    Muston, Dominic
    Tekin, Cumhur
    Keefe, Steve
    Monberg, Matthew
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A38 - A38
  • [2] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN GREECE
    Yfantopoulos, N.
    Gountas, I
    Swami, S.
    Skroumpelos, A.
    Karokis, A.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S62 - S62
  • [3] Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer
    Shi, Yang
    Chen, Jigang
    Shi, Bo
    Liu, Aihua
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 164 (02) : 379 - 385
  • [4] Pembrolizumab for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis
    Barrington, David
    Riedinger, Courtney
    Haight, Paulina
    Tubbs, Crystal
    Cohn, David
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S19 - S19
  • [5] COST-EFFECTIVENESS OF PEMBROLIZUMAB IN FIRST-LINE TREATMENT OF PD-L1 POSITIVE PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Nedzesky, J.
    Veenstra, D.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S343 - S343
  • [6] Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States
    Borse, Rebekah H.
    Ramakrishnan, Karthik
    Gandhi, Jyotika
    Dhankhar, Praveen
    Chirovsky, Diana
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 954 - 965
  • [7] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB plus CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN JAPAN
    Akai, M.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S69 - S69
  • [8] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
  • [9] Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer
    Lin, Ying-tao
    Wang, Chang
    He, Xiao-yan
    Yao, Qi-min
    Chen, Jian
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [10] Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
    Shankaran, Veena
    Ortendahl, Jesse D.
    Purdum, Anna G.
    Bolinder, Bjorn
    Anene, Ayanna M.
    Sun, Gordon H.
    Bentley, Tanya G. K.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 65 - 72
12345